{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:46Z","timestamp":1792842286487,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007176","name":"Scuola Superiore Sant'Anna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007176","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiac fibrosis is characterized by the deposition of extracellular matrix proteins in the spaces between cardiomyocytes following both acute and chronic tissue damage events, resulting in the remodeling and stiffening of heart tissue. Fibrosis plays an important role in the pathogenesis of many cardiovascular disorders, including heart failure and myocardial infarction. Several studies have identified fibroblasts, which are induced to differentiate into myofibroblasts in response to various types of damage, as the most important cell types involved in the fibrotic process. Some drugs, such as inhibitors of the renin\u2013angiotensin\u2013aldosterone system, have been shown to be effective in reducing cardiac fibrosis. There are currently no drugs with primarily anti-fibrotic action approved for clinical use, as well as the evidence of a clinical efficacy of these drugs is extremely limited, despite the numerous encouraging results from experimental studies. A new approach is represented by the use of CAR-T cells engineered in vivo using lipid nanoparticles containing mRNA coding for a receptor directed against the FAP protein, expressed by cardiac myofibroblasts. This strategy has proved to be safe and effective in reducing myocardial fibrosis and improving cardiac function in mouse models of cardiac fibrosis. Clinical studies are required to test this novel approach in humans.<\/jats:p>","DOI":"10.1007\/s10741-022-10279-x","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T22:02:27Z","timestamp":1665525747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy"],"prefix":"10.1007","author":[{"given":"Paolo","family":"Morfino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"G\u00e1lvez-Mont\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"issue":"1","key":"10279_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cardiores.2004.06.006","volume":"64","author":"MW Schellings","year":"2004","unstructured":"Schellings MW, Pinto YM, Heymans S (2004) Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 64(1):24\u201331","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10279_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199\u2013210","journal-title":"J Pathol"},{"issue":"1","key":"10279_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wang L, Wang M et al (2022) Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther 7(1):206","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10279_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1165\/rcmb.2019-0092OC","volume":"62","author":"K Kato","year":"2020","unstructured":"Kato K, Logsdon NJ, Shin YJ et al (2020) Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. Am J Respir Cell Mol Biol 62(5):633\u2013644","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10279_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1242\/dmm.012062","volume":"7","author":"M Giannandrea","year":"2014","unstructured":"Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 7(2):193\u2013203","journal-title":"Dis Model Mech"},{"issue":"6","key":"10279_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG (2021) Cardiac fibrosis. Cardiovasc Res 117(6):1450\u20131488","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10279_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg EM, Tarnavski O, Zeisberg M et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13(8):952\u2013961","journal-title":"Nat Med"},{"issue":"3","key":"10279_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00441-016-2431-9","volume":"365","author":"V Talman","year":"2016","unstructured":"Talman V, Ruskoaho H (2016) Cardiac fibrosis in myocardial infarction\u2013from repair and remodeling to regeneration. Cell Tissue Res 365(3):563\u2013581","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10279_CR9","first-page":"21","volume":"20","author":"S Nattel","year":"2005","unstructured":"Nattel S, Shiroshita-Takeshita A, Cardin S et al (2005) Mechanisms of atrial remodeling and clinical relevance. Curr Opin Cardiol 20(1):21\u201325","journal-title":"Curr Opin Cardiol"},{"issue":"3","key":"10279_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cphy.c160046","volume":"7","author":"MN Nguyen","year":"2017","unstructured":"Nguyen MN, Kiriazis H, Gao XM et al (2017) Cardiac fibrosis and arrhythmogenesis. Compr Physiol 7(3):1009\u20131049","journal-title":"Compr Physiol"},{"key":"10279_CR11","doi-asserted-by":"crossref","unstructured":"Spach MS, Dolber PC, Heidlage JF (1989) Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry. Circul Res 65(6):1612\u201331","DOI":"10.1161\/01.RES.65.6.1612"},{"key":"10279_CR12","doi-asserted-by":"crossref","unstructured":"Vergaro G, Aimo A, Rapezzi C et al (2022) Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail\u00a0Aug 3","DOI":"10.1002\/ejhf.2650"},{"issue":"20","key":"10279_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020358","volume":"10","author":"A Pucci","year":"2021","unstructured":"Pucci A, Aimo A, Musetti V et al (2021) Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc 10(20):e020358","journal-title":"J Am Heart Assoc"},{"key":"10279_CR14","doi-asserted-by":"crossref","unstructured":"de Boer RA, De Keulenaer G, Bauersachs J et al (2019) Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 21(3):272\u2013285","DOI":"10.1002\/ejhf.1406"},{"key":"10279_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","volume":"146","author":"S Hinderer","year":"2019","unstructured":"Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis \u2013 a short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146:77\u201382","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"10279_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","volume":"52","author":"L Iles","year":"2008","unstructured":"Iles L, Pfluger H, Phrommintikul A et al (2008) Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52(19):1574\u20131580","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10279_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.14336\/AD.2020.0604","volume":"11","author":"Y Ding","year":"2020","unstructured":"Ding Y, Wang Y, Zhang W et al (2020) Roles of biomarkers in myocardial fibrosis. Aging Dis 11(5):1157\u20131174","journal-title":"Aging Dis"},{"issue":"22","key":"10279_CR18","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","volume":"65","author":"B Lopez","year":"2015","unstructured":"Lopez B, Gonzalez A, Ravassa S et al (2015) Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65(22):2449\u20132456","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10279_CR19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.108.811877","volume":"119","author":"RS Oakes","year":"2009","unstructured":"Oakes RS, Badger TJ, Kholmovski EG et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119(13):1758\u20131767","journal-title":"Circulation"},{"issue":"11","key":"10279_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","volume":"56","author":"R O'Hanlon","year":"2010","unstructured":"O\u2019Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867\u2013874","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10279_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2020.10.046","volume":"77","author":"A Zegard","year":"2021","unstructured":"Zegard A, Okafor O, de Bono J et al (2021) Myocardial fibrosis as a predictor of sudden death in patients with coronary artery disease. J Am Coll Cardiol 77(1):29\u201341","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10279_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMcibr2201182","volume":"386","author":"SL Friedman","year":"2022","unstructured":"Friedman SL (2022) Fighting cardiac fibrosis with CAR T cells. N Engl J Med 386(16):1576\u20131578","journal-title":"N Engl J Med"},{"issue":"8","key":"10279_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis GA, Dodd S, Clayton D et al (2021) Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med 27(8):1477\u20131482","journal-title":"Nat Med"},{"issue":"6576","key":"10279_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tombacz I, Yadegari A et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375(6576):91\u201396","journal-title":"Science"},{"issue":"4","key":"10279_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71(4):549\u2013574","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10279_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0008-6363(00)00044-4","volume":"46","author":"JM Schnee","year":"2000","unstructured":"Schnee JM, Hsueh WA (2000) Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46(2):264\u2013268","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10279_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","volume":"102","author":"CG Brilla","year":"2000","unstructured":"Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102(12):1388\u20131393","journal-title":"Circulation"},{"issue":"3","key":"10279_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/01.CIR.104.3.286","volume":"104","author":"B Lopez","year":"2001","unstructured":"Lopez B, Querejeta R, Varo N et al (2001) Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104(3):286\u2013291","journal-title":"Circulation"},{"issue":"21","key":"10279_CR29","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","volume":"105","author":"J Diez","year":"2002","unstructured":"Diez J, Querejeta R, Lopez B et al (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512\u20132517","journal-title":"Circulation"},{"issue":"6","key":"10279_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","volume":"1","author":"YJ Shimada","year":"2013","unstructured":"Shimada YJ, Passeri JJ, Baggish AL et al (2013) Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart failure 1(6):480\u2013487","journal-title":"JACC Heart failure"},{"issue":"7","key":"10279_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","volume":"26","author":"CG Brilla","year":"1994","unstructured":"Brilla CG, Zhou G, Matsubara L et al (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26(7):809\u2013820","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"10279_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","volume":"4","author":"W Kosmala","year":"2011","unstructured":"Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al (2011) A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 4(12):1239\u20131249","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10279_CR33","first-page":"320","volume":"99","author":"W Kosmala","year":"2013","unstructured":"Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al (2013) Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart (British Cardiac Society) 99(5):320\u2013326","journal-title":"Heart (British Cardiac Society)"},{"issue":"18","key":"10279_CR34","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","volume":"54","author":"GJ Mak","year":"2009","unstructured":"Mak GJ, Ledwidge MT, Watson CJ et al (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54(18):1674\u20131682","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10279_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B et al (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Cardiac Fail 17(8):634\u2013642","journal-title":"J Cardiac Fail"},{"issue":"22","key":"10279_CR36","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B et al (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 102(22):2700\u20132706","journal-title":"Rales Investigators Circulation"},{"key":"10279_CR37","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England J Med 2;341(10):709\u201317","DOI":"10.1056\/NEJM199909023411001"},{"issue":"18","key":"10279_CR38","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"W Iraqi","year":"2009","unstructured":"Iraqi W, Rossignol P, Angioi M et al (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119(18):2471\u20132479","journal-title":"Circulation"},{"issue":"9","key":"10279_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ejhf.1194","volume":"20","author":"S Ravassa","year":"2018","unstructured":"Ravassa S, Trippel T, Bach D et al (2018) Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20(9):1290\u20131299","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10279_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00395-018-0690-1","volume":"113","author":"F Hofmann","year":"2018","unstructured":"Hofmann F (2018) A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology. Basic Res Cardiol 113(4):31","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"10279_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/annrheumdis-2017-212489","volume":"77","author":"AE Matei","year":"2018","unstructured":"Matei AE, Beyer C, Gyorfi AH et al (2018) Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis 77(3):459","journal-title":"Ann Rheum Dis"},{"key":"10279_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1874312901206010156","volume":"6","author":"S Nakerakanti","year":"2012","unstructured":"Nakerakanti S, Trojanowska M (2012) The role of TGF-beta receptors in fibrosis. Open Rheumatol J 6:156\u2013162","journal-title":"Open Rheumatol J"},{"issue":"4","key":"10279_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","volume":"12","author":"RM Burke","year":"2019","unstructured":"Burke RM, Lighthouse JK, Mickelsen DM et al (2019) Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 12(4):e005565","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10279_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","volume":"94","author":"AM Kapoun","year":"2004","unstructured":"Kapoun AM, Liang F, O\u2019Young G et al (2004) B-Type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94(4):453\u2013461","journal-title":"Circ Res"},{"issue":"5","key":"10279_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","volume":"76","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW, Claggett BL, O\u2019Meara E et al (2020) Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol 76(5):503\u2013514","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10279_CR46","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","volume":"115","author":"M Sun","year":"2007","unstructured":"Sun M, Chen M, Dawood F et al (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115(11):1398\u20131407","journal-title":"Circulation"},{"issue":"13","key":"10279_CR47","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109(13):1594\u20131602","journal-title":"Circulation"},{"issue":"25","key":"10279_CR48","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25):3133\u20133140","journal-title":"Circulation"},{"issue":"10","key":"10279_CR49","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1161\/CIRCULATIONAHA.108.802918","volume":"119","author":"T Hamid","year":"2009","unstructured":"Hamid T, Gu Y, Ortines RV et al (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119(10):1386\u20131397","journal-title":"Circulation"},{"issue":"1","key":"10279_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1871523011312010004","volume":"12","author":"F Roubille","year":"2013","unstructured":"Roubille F, Kritikou E, Busseuil D et al (2013) Colchicine: an old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem 12(1):14\u201323","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"issue":"4","key":"10279_CR51","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1073\/pnas.89.4.1256","volume":"89","author":"TJ Lampidis","year":"1992","unstructured":"Lampidis TJ, Kolonias D, Savaraj N et al (1992) Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents. Proc Natl Acad Sci U S A 89(4):1256\u20131260","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"240","key":"10279_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijcard.2017.03.126","volume":"1","author":"M Akodad","year":"2017","unstructured":"Akodad M, Fauconnier J, Sicard P et al (2017) Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. Int J Cardiol 1(240):347\u2013353","journal-title":"Int J Cardiol"},{"issue":"26","key":"10279_CR53","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381(26):2497\u20132505","journal-title":"N Engl J Med"},{"issue":"10","key":"10279_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.acvd.2020.04.007","volume":"113","author":"M Akodad","year":"2020","unstructured":"Akodad M, Sicard P, Fauconnier J et al (2020) Colchicine and myocardial infarction: a review. Arch Cardiovasc Dis 113(10):652\u2013659","journal-title":"Arch Cardiovasc Dis"},{"issue":"11","key":"10279_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","volume":"144","author":"N Mewton","year":"2021","unstructured":"Mewton N, Roubille F, Bresson D et al (2021) Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation 144(11):859\u2013869","journal-title":"Circulation"},{"issue":"8","key":"10279_CR56","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jacc.2003.11.043","volume":"43","author":"T Ogata","year":"2004","unstructured":"Ogata T, Miyauchi T, Sakai S et al (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43(8):1481\u20131488","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10279_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1874467211205020255","volume":"5","author":"S Sarma","year":"2012","unstructured":"Sarma S (2012) Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? Curr Mol Pharmacol 5(2):255\u2013263","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"10279_CR58","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cmet.2011.10.001","volume":"14","author":"S Oka","year":"2011","unstructured":"Oka S, Alcendor R, Zhai P et al (2011) PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 14(5):598\u2013611","journal-title":"Cell Metab"},{"issue":"3","key":"10279_CR59","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/hr.2010.243","volume":"34","author":"C Yamamoto","year":"2011","unstructured":"Yamamoto C, Fukuda N, Jumabay M et al (2011) Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res 34(3):348\u2013353","journal-title":"Hypertens Res"},{"issue":"10","key":"10279_CR60","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/01.ATV.0000142813.33538.82","volume":"24","author":"S Wolfrum","year":"2004","unstructured":"Wolfrum S, Dendorfer A, Rikitake Y et al (2004) Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase\/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24(10):1842\u20131847","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10279_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.109.131243","volume":"54","author":"SA Chang","year":"2009","unstructured":"Chang SA, Kim YJ, Lee HW et al (2009) Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension 54(3):591\u2013597","journal-title":"Hypertension"},{"issue":"1","key":"10279_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clinthera.2011.11.002","volume":"34","author":"E Abulhul","year":"2012","unstructured":"Abulhul E, McDonald K, Martos R et al (2012) Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther 34(1):91\u2013100","journal-title":"Clin Ther"},{"issue":"7","key":"10279_CR63","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/jim-2016-000092","volume":"64","author":"YY Chang","year":"2016","unstructured":"Chang YY, Wu YW, Lee JK et al (2016) Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naive patients with hypertension with atherosclerosis. J Investig Med 64(7):1194\u20131199","journal-title":"J Investig Med"},{"issue":"3","key":"10279_CR64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijcard.2009.12.028","volume":"146","author":"E Ashton","year":"2011","unstructured":"Ashton E, Windebank E, Skiba M et al (2011) Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 146(3):404\u2013407","journal-title":"Int J Cardiol"},{"issue":"22","key":"10279_CR65","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22):2248\u20132261","journal-title":"N Engl J Med"},{"issue":"9645","key":"10279_CR66","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 372(9645):1231\u20131239","journal-title":"Lancet (London, England)"},{"key":"10279_CR67","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fphar.2017.00186","volume":"8","author":"L Fang","year":"2017","unstructured":"Fang L, Murphy AJ, Dart AM (2017) A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol 8:186","journal-title":"Front Pharmacol"},{"issue":"5","key":"10279_CR68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00395-008-0739-7","volume":"103","author":"S Frantz","year":"2008","unstructured":"Frantz S, Hu K, Adamek A et al (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103(5):485\u2013492","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"10279_CR69","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/01.CIR.0000020689.12472.E0","volume":"106","author":"F Kuwahara","year":"2002","unstructured":"Kuwahara F, Kai H, Tokuda K et al (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106(1):130\u2013135","journal-title":"Circulation"},{"issue":"9779","key":"10279_CR70","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(11)60546-1","volume":"377","author":"D Bouros","year":"2011","unstructured":"Bouros D (2011) Pirfenidone for idiopathic pulmonary fibrosis. Lancet (London, England) 377(9779):1727\u20131729","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10279_CR71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","volume":"4","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Wuyts W, Renzoni E et al (2016) Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4(5):381\u2013389","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10279_CR72","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10741-021-10175-w","volume":"27","author":"A Aimo","year":"2022","unstructured":"Aimo A, Spitaleri G, Panichella G et al (2022) Pirfenidone as a novel cardiac protective treatment. Heart Fail Rev 27(2):525\u2013532","journal-title":"Heart Fail Rev"},{"issue":"1\u20133","key":"10279_CR73","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590(1\u20133):400\u2013408","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10279_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028134","volume":"6","author":"Q Shi","year":"2011","unstructured":"Shi Q, Liu X, Bai Y et al (2011) In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS ONE 6(11):e28134","journal-title":"PLoS ONE"},{"key":"10279_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104694","volume":"155","author":"A Aimo","year":"2020","unstructured":"Aimo A, Cerbai E, Bartolucci G et al (2020) Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155:104694","journal-title":"Pharmacol Res"},{"issue":"3","key":"10279_CR76","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/TP.0b013e3181ae3392","volume":"88","author":"GA Visner","year":"2009","unstructured":"Visner GA, Liu F, Bizargity P et al (2009) Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 88(3):330\u2013338","journal-title":"Transplantation"},{"issue":"18","key":"10279_CR77","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","volume":"129","author":"J Du","year":"2017","unstructured":"Du J, Paz K, Flynn R et al (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood 129(18):2570\u20132580","journal-title":"Blood"},{"issue":"1","key":"10279_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000351179","volume":"126","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wu Y, Chen J et al (2013) Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology 126(1):1\u201311","journal-title":"Cardiology"},{"issue":"1","key":"10279_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/hr.2011.139","volume":"35","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Yamashita N, Izumi Y et al (2012) The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 35(1):34\u201340","journal-title":"Hypertens Res"},{"key":"10279_CR80","doi-asserted-by":"crossref","unstructured":"AlAnsari S, Southern B, Riaz H et al (2019) Responses to pirfenidone treatment in patients with idiopathic pulmonary fibrosis is not associated with changes in echocardiographic parameters of left ventricular structure and function. J Cardiac Fail\u00a02019\/08\/01\/;25(8, Supplement):S27","DOI":"10.1016\/j.cardfail.2019.07.074"},{"key":"10279_CR81","doi-asserted-by":"crossref","unstructured":"AlAnsari S, Southern BD, Sharma V et al (2020) Pirfenidone is associated with decreased indexed end diastolic and systolic volumes in patients with HFpEF and a known history of idiopathic pulmonary fibrosis. J Cardiac Fail\u00a02020\/10\/01\/;26(10, Supplement):S25","DOI":"10.1016\/j.cardfail.2020.09.080"},{"issue":"1","key":"10279_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)62228-6","volume":"166","author":"S Heymans","year":"2005","unstructured":"Heymans S, Lupu F, Terclavers S et al (2005) Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166(1):15\u201325","journal-title":"Am J Pathol"},{"issue":"4","key":"10279_CR83","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/01.HYP.0000208840.30778.00","volume":"47","author":"H Matsusaka","year":"2006","unstructured":"Matsusaka H, Ide T, Matsushima S et al (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47(4):711\u2013717","journal-title":"Hypertension"},{"issue":"1","key":"10279_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacc.2006.02.055","volume":"48","author":"MP Hudson","year":"2006","unstructured":"Hudson MP, Armstrong PW, Ruzyllo W et al (2006) Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 48(1):15\u201320","journal-title":"J Am Coll Cardiol"},{"issue":"9169","key":"10279_CR85","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure (1999) Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England) 353(9169):2001\u20132007","journal-title":"Lancet (London, England)"},{"key":"10279_CR86","doi-asserted-by":"crossref","unstructured":"Travers JG, Tharp CA, Rubino M et al (2022) Therapeutic targets for cardiac fibrosis: from old school to next-gen. J Clin Invest 1;132(5)","DOI":"10.1172\/JCI148554"},{"issue":"Suppl 5","key":"10279_CR87","first-page":"V16","volume":"22","author":"HN Sabbah","year":"1999","unstructured":"Sabbah HN (1999) The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol 22(Suppl 5):V16-20","journal-title":"Clin Cardiol"},{"issue":"6","key":"10279_CR88","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1124\/mol.106.028951","volume":"70","author":"X Liu","year":"2006","unstructured":"Liu X, Sun SQ, Hassid A et al (2006) cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1\/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 70(6):1992\u20132003","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10279_CR89","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCRESAHA.116.309538","volume":"119","author":"MC Woodall","year":"2016","unstructured":"Woodall MC, Woodall BP, Gao E et al (2016) Cardiac fibroblast GRK2 deletion enhances contractility and remodeling following ischemia\/reperfusion injury. Circ Res 119(10):1116\u20131127","journal-title":"Circ Res"},{"key":"10279_CR90","doi-asserted-by":"crossref","unstructured":"Raake PW, Schlegel P, Ksienzyk J et al (2013) AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J\u00a034(19):1437\u201347","DOI":"10.1093\/eurheartj\/ehr447"},{"issue":"4","key":"10279_CR91","first-page":"548","volume":"43","author":"F Nantel","year":"1993","unstructured":"Nantel F, Bonin H, Emorine LJ et al (1993) The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 43(4):548\u2013555","journal-title":"Mol Pharmacol"},{"key":"10279_CR92","doi-asserted-by":"crossref","unstructured":"Michel LYM, Farah C, Balligand JL (2020) The beta3 adrenergic receptor in healthy and pathological cardiovascular tissues. Cells\u00a02;9(12)","DOI":"10.3390\/cells9122584"},{"issue":"5","key":"10279_CR93","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.yjmcc.2009.06.005","volume":"47","author":"AL Moens","year":"2009","unstructured":"Moens AL, Leyton-Mange JS, Niu X et al (2009) Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol 47(5):576\u2013585","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"10279_CR94","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1124\/jpet.120.000140","volume":"376","author":"M Kamiya","year":"2021","unstructured":"Kamiya M, Asai K, Maejima Y et al (2021) Beta 3-adrenergic receptor agonist prevents diastolic dysfunction in an angiotensin II-induced cardiomyopathy mouse model. J Pharmacol Exp Ther 376(3):473\u2013481","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"10279_CR95","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jacc.2011.12.046","volume":"59","author":"X Niu","year":"2012","unstructured":"Niu X, Watts VL, Cingolani OH et al (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59(22):1979\u20131987","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10279_CR96","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.714","volume":"19","author":"H Bundgaard","year":"2017","unstructured":"Bundgaard H, Axelsson A, Hartvig Thomsen J et al (2017) The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail 19(4):566\u2013575","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10279_CR97","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69","journal-title":"Blood Cancer J"},{"issue":"1","key":"10279_CR98","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y et al (2017) New development in CAR-T cell therapy. J Hematol Oncol 10(1):53","journal-title":"J Hematol Oncol"},{"issue":"6382","key":"10279_CR99","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU et al (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365","journal-title":"Science"},{"issue":"11","key":"10279_CR100","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","volume":"53","author":"Y Liu","year":"2017","unstructured":"Liu Y, Chen X, Han W et al (2017) Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 53(11):597\u2013608","journal-title":"Drugs Today (Barc)"},{"issue":"7774","key":"10279_CR101","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573(7774):430\u2013433","journal-title":"Nature"},{"issue":"Suppl 1","key":"10279_CR102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer D, Brentjens R (2019) CAR T-cell therapy: Full speed ahead. Hematol Oncol 37(Suppl 1):95\u2013100","journal-title":"Hematol Oncol"},{"key":"10279_CR103","doi-asserted-by":"crossref","unstructured":"Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 10;3(95):95ra73","DOI":"10.1126\/scitranslmed.3002842"},{"issue":"1","key":"10279_CR104","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A et al (2020) CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol 2(1):97\u2013109","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10279_CR105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-018-0690-1","volume":"20","author":"A Asnani","year":"2018","unstructured":"Asnani A (2018) Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 20(6):44","journal-title":"Curr Oncol Rep"},{"issue":"22","key":"10279_CR106","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Moon E, Carpenito C et al (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053\u20139061","journal-title":"Cancer Res"},{"issue":"4","key":"10279_CR107","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW et al (2018) mRNA vaccines \u2013 a new era in vaccinology. Nat Rev Drug Discovery 17(4):261\u2013279","journal-title":"Nat Rev Drug Discovery"},{"key":"10279_CR108","doi-asserted-by":"crossref","unstructured":"Boumsell L, Coppin H, Pham D et al (1980) An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med 1;152(1):229\u201334","DOI":"10.1084\/jem.152.1.229"},{"issue":"12","key":"10279_CR109","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.116.308643","volume":"118","author":"H Kaur","year":"2016","unstructured":"Kaur H, Takefuji M, Ngai CY et al (2016) Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice. Circ Res 118(12):1906\u20131917","journal-title":"Circ Res"},{"issue":"3","key":"10279_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11936-018-0617-z","volume":"20","author":"P Alvarez","year":"2018","unstructured":"Alvarez P, Briasoulis A (2018) Immune modulation in heart failure: the promise of novel biologics. Curr Treat Options Cardiovasc Med 20(3):26","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"9","key":"10279_CR111","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011451","volume":"13","author":"MA Zayed","year":"2020","unstructured":"Zayed MA (2020) Immune modulation of coronary atherosclerosis with anticytokine treatment. Circ Cardiovasc Imaging 13(9):e011451","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10279_CR112","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8(10):1219\u20131226","journal-title":"Cancer Discov"},{"issue":"2","key":"10279_CR113","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM et al (2020) Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol 2(2):193\u2013203","journal-title":"JACC CardioOncol"},{"issue":"25","key":"10279_CR114","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG et al (2019) Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 74(25):3099\u20133108","journal-title":"J Am Coll Cardiol"},{"key":"10279_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.886553","volume":"9","author":"K Schimmel","year":"2022","unstructured":"Schimmel K, Ichimura K, Reddy S et al (2022) Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Front Cardiovasc Med 9:886553","journal-title":"Front Cardiovasc Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10279-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T23:06:50Z","timestamp":1665529610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10279-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":115,"alternative-id":["10279"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10279-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"3 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}